Triple

T5872958
Position Surface form Disambiguated ID Type / Status
Subject CPMP E130560 entity
Predicate successor P78 FINISHED
Object Committee for Medicinal Products for Human Use E139009 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Committee for Medicinal Products for Human Use | Statement: [CPMP, successor, Committee for Medicinal Products for Human Use]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Committee for Medicinal Products for Human Use
Context triple: [CPMP, successor, Committee for Medicinal Products for Human Use]
  • A. Committee for Medicinal Products for Human Use chosen
    The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
  • B. Committee for Herbal Medicinal Products
    The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
  • C. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • D. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • E. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c0085047dc8190af24e311edad3c07 completed March 22, 2026, 3:18 p.m.
NER Named-entity recognition batch_69c035f99b788190b5b06d83b9499bfa completed March 22, 2026, 6:33 p.m.
NED1 Entity disambiguation (via context triple) batch_69c107fd138c819092096f473be3e4cf completed March 23, 2026, 9:29 a.m.
Created at: March 22, 2026, 3:56 p.m.